Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Antiviral treatment of HCV in thalassemia has raised concerns of ribavirin-induced hemolysis and increased iron loading. Blood Transfusion in Thalassemic patients are a known high risk for acquiring hepatitis C. The investigators are trying the PEGASYS (Peginterferon alpha-2a(40 KD)) plus Ribavirin in Thalassemic patients with HCV.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Baqiyatallah Medical Sciences University
• Collaborators: Baqiyatallah Research Center for Gastroenterology and Liver Diseases; Guilan Research Center for Gastroenterology and Liver Diseases; Guilan University of Medical Sciences; Tabriz Research Center for Gastroenterology and Liver Diseases; Tehran Hepatitis Center
• Treatments: Interferon-alpha; Peginterferon alfa-2a; Ribavirin

Criteria

Inclusion Criteria:

• HCV RNA positive

• Age older than 12 years

Exclusion Criteria:

• Ongoing pregnancy or breast feeding

• History (Hx) of Hepatocellular Carcinoma (HCC)

• Hx of alcoholic liver disease

• Hx of bleeding from esophageal varices

• Hx of hemochromatosis

• Hx of autoimmune hepatitis

• Hx of Suicidal attempt

• Hx of cerebrovascular dis

• Hx of severe retinopathy

• Hx of severe psoriasis

• Hx of scleroderma

• Hx of metabolic liver disease

• Hx of Systemic Lupus Erythematosus (SLE)